Literature DB >> 11817323

Nucleic acid vaccines: tasks and tactics.

B S McKenzie1, A J Corbett, J L Brady, C M Dyer, R A Strugnell, S J Kent, D R Kramer, J S Boyle, A M Lew.   

Abstract

There are no adequate vaccines against some of the new or reemerged infectious scourges such as HIV and TB. They may require strong and enduring cell-mediated immunity to be elicited. This is quite a task, as the only known basis of protection by current commercial vaccines is antibody. As DNA or RNA vaccines may induce both cell-mediated and humoral immunity, great interest has been shown in them. However, doubt remains whether their efficacy will suffice for their clinical realization. We look at the various tactics to increase the potency of nucleic acid vaccines and divided them broadly under those affecting delivery and those affecting immune induction. For delivery, we have considered ways of improving uptake and the use of bacterial, replicon or viral vectors. For immune induction, we considered aspects of immunostimulatory CpG motifs, coinjection of cytokines or costimulators and alterations of the antigen, its cellular localization and its anatomical localization including the use of ligand-targeting to lymphoid tissue. We also thought that mucosal application of DNA deserved a separate section. In this review, we have taken the liberty to discuss these enhancement methods, whenever possible, in the context of the underlying mechanisms that might argue for or against these strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817323     DOI: 10.1385/IR:24:3:225

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  190 in total

1.  Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.

Authors:  T M Allen; T U Vogel; D H Fuller; B R Mothé; S Steffen; J E Boyson; T Shipley; J Fuller; T Hanke; A Sette; J D Altman; B Moss; A J McMichael; D I Watkins
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

2.  Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene.

Authors:  W F Cheng; C F Hung; C Y Chai; K F Hsu; L He; C M Rice; M Ling; T C Wu
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

3.  The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine.

Authors:  E B Gurvich
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

Review 4.  Antigen processing for amateurs and professionals.

Authors:  I Mellman; S J Turley; R M Steinman
Journal:  Trends Cell Biol       Date:  1998-06       Impact factor: 20.808

5.  DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity.

Authors:  J S Boyle; A Silva; J L Brady; A M Lew
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

6.  Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes.

Authors:  J J Kim; M L Bagarazzi; N Trivedi; Y Hu; K Kazahaya; D M Wilson; R Ciccarelli; M A Chattergoon; K Dang; S Mahalingam; A A Chalian; M G Agadjanyan; J D Boyer; B Wang; D B Weiner
Journal:  Nat Biotechnol       Date:  1997-07       Impact factor: 54.908

7.  Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.

Authors:  W W Leitner; H Ying; D A Driver; T W Dubensky; N P Restifo
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

8.  Selected strategies to augment polynucleotide immunization.

Authors:  R M Conry; G Widera; A F LoBuglio; J T Fuller; S E Moore; D L Barlow; J Turner; N S Yang; D T Curiel
Journal:  Gene Ther       Date:  1996-01       Impact factor: 5.250

9.  IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine.

Authors:  K Q Xin; K Hamajima; S Sasaki; T Tsuji; S Watabe; E Okada; K Okuda
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

10.  Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

Authors:  S J Kent; A Zhao; S J Best; J D Chandler; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  4 in total

1.  Envelope virus-mimetic nanovaccines by hybridizing bioengineered cell membranes with bacterial vesicles.

Authors:  Mengmeng Zhang; Lu Wang; Jinyao Liu; Yan Pang
Journal:  iScience       Date:  2022-05-30

2.  Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines.

Authors:  Steven R Little; David M Lynn; Qing Ge; Daniel G Anderson; Sidharth V Puram; Jianzhu Chen; Herman N Eisen; Robert Langer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

3.  Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.

Authors:  Rui Tada; Shoko Muto; Tomoko Iwata; Akira Hidaka; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki
Journal:  BMC Res Notes       Date:  2017-01-26

4.  A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge.

Authors:  Yu-Li Lin; Yen-Hung Chow; Li-Min Huang; Szu-Min Hsieh; Pei-Yun Cheng; Kai-Chieh Hu; Bor-Luen Chiang
Journal:  Sci Rep       Date:  2018-07-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.